Drug makers losing a bid to foil generic painkillers
In coming months, generic drug producers are expected to introduce cheaper versions of OxyContin and Opana, two long-acting narcotic painkillers, or opioids, that are widely abused. But in hopes of delaying the move to generics, the makers of the brand name drugs, Purdue Pharma and Endo Pharmaceuticals, have introduced versions that are more resistant to crushing or melting, techniques abusers use to release the pills' narcotic payloads. The two drug makers, which say they are motivated not by profit but by public safety, have also been waging a multifront political and legal war to block sales of generics that are not tamper-resistant.
- ICD-10: Minimizing the Financial Hit
- Hospital Compare Adds Infection, Stroke, Readmissions Data
- 3 Favorite Nursing Trends of 2013
- How One Provider is Saving Millions on Imaging Equipment
- HIT in 2014: Portal Perils and Half-Built Houses
- SLIDESHOW: HL20 — 20 People Who Are Making a Difference in Healthcare - 2013
- State Health Disparities Trace Medicaid Expansion
- Q&A: Banner CEO on 'Getting the Cost Out'
- Healthcare Unions Eye Gains in 2014
- AMCs React to Being Shut Out of Some Exchange Plans